

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

June 3 2019



(HealthDay)—For frail and elderly patients with advanced

gastroesophageal cancer (aGOAC), low-dose chemotherapy is noninferior to high-dose chemotherapy for progression-free survival, according to a study presented at the annual meeting of the American Society for Clinical Oncology, held from May 31 to June 4 in Chicago.

Peter S. Hall, Ph.D., from the University of Edinburgh in the United Kingdom, and colleagues randomly assigned 514 [patients](#) with aGOAC who were unsuitable for full-dose epirubin/oxaliplatin/capecitabine due to age or frailty but fit for oxaliplatin/capecitabine. Patients were randomly assigned in a 1:1:1 ratio to dose level A, dose level B (80 percent of level A dose), and dose level C (60 percent of level A dose).

The researchers found that at 12 weeks, noninferiority of [progression-free survival](#) was confirmed for level B versus A (hazard ratio, 1.09; 95 percent confidence interval, 0.89 to 1.32) and level C versus A (hazard ratio, 1.10; 95 percent confidence interval, 0.90 to 1.33). Compared with level A or B patients, level C patients had less toxicity and better overall treatment utility outcomes (percentage with good outcome: 43 versus 35 and 36 percent, respectively). Level C yielded the best overall treatment utility even for younger, less frail, and better performance-status patients.

"We hope our finding helps patients make a more informed choice, between low-dose chemotherapy and no chemotherapy at all, with the knowledge that that low-dose chemotherapy can prove beneficial and still allow them to maintain some quality of life while slowing the progression of the disease," Hall said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: [Abstract](#)
[More Information](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: ASCO: low-dose chemo benefits advanced gastroesophageal cancer (2019, June 3)
retrieved 3 February 2024 from

<https://medicalxpress.com/news/2019-06-asco-low-dose-chemo-benefits-advanced.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.